The Medicinal Chemistry of Novel Molecules in Clinical Trials for Tuberculosis Treatment

被引：5

作者：

Branco, Frederico S. C. ^{[1
,2
]}

Pinto, Angelo C. ^{[1
]}

Boechat, Nubia ^{[2
]}

机构：

[1] Univ Fed Rio de Janeiro, Inst Quim, BR-21941909 Rio De Janeiro, RJ, Brazil

[2] Fundacao Oswaldo Cruz FIOCRUZ, Lab Sintese 1, Inst Tecnol Farmacos Farmanquinhos, Dept Sintese Organ, BR-21041250 Rio De Janeiro, RJ, Brazil

来源：

REVISTA VIRTUAL DE QUIMICA | 2012年 / 4卷 / 03期

关键词：

Tuberculosis; clinical trial; medicinal chemistry; drug design;

D O I：

10.5935/1984-6835.20120023

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Tuberculosis is a serious public health problem, especially in underdeveloped or developing countries. The first line anti-TB treatment was developed more than 40 years ago. In addition to the development of strains of Mycobacterium tuberculosis resistant to multiple drugs and co-infection with the AIDS virus, has worsened the situation of this disease worldwide. The urgent need for new therapeutic options active against multidrug-resistant strains and concurrently capable to be used with AIDS treatment has led industries, governments and nongovernmental organizations to develop new drugs. This review describes the process of developing new anti-TB drugs and the chemistry of new molecules drug candidates that are in clinical trials for this disease listed in the global portfolio of Stop TB Partnership.

引用

页码：287 / 328

页数：42

共 60 条

[1] In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs [J].

Alcalá, L ;

Ruiz-Serrano, MJ ;

Turégano, CPF ;

Garcia de Viedma, D ;

Díaz-Infantes, M ;

Marín-Arriaza, M ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :416-417

[2] Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480 [J].

Alffenaar, J. W. C. ;

van der Laan, T. ;

Simons, S. ;

van der Werf, T. S. ;

van de Kasteele, P. J. ;

de Neeling, H. ;

van Soolingen, D. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) :1287-1289

[3] INTERMEDIATES IN THE PAAL-KNORR SYNTHESIS OF PYRROLES [J].

AMARNATH, V ;

ANTHONY, DC ;

AMARNATH, K ;

VALENTINE, WM ;

WETTERAU, LA ;

GRAHAM, DG .

JOURNAL OF ORGANIC CHEMISTRY, 1991, 56 (24) :6924-6931

[4] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[5]

Andries KJLM, 2005, Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases, Patent No. [WO2005117875, 2005117875]

[6]

Arora S., 2004, 44 INT C ANT AG CHEM

[7]

Arora S.K., 2004, International Patent, Patent No. [2004026828, WO/2004/026828]

[8]

Baker W.R., 1997, Patent No. [9701562 A1, 9701562]

[9] Oxazolidinone structure-activity relationships leading to linezolid [J].

Barbachyn, MR ;

Ford, CW .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (18) :2010-2023

[10] Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity [J].

Barbachyn, MR ;

Hutchinson, DK ;

Brickner, SJ ;

Cynamon, MH ;

Kilburn, JO ;

Klemens, SP ;

Glickman, SE ;

Grega, KC ;

Hendges, SK ;

Toops, DS ;

Ford, CW ;

Zurenko, GE .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :680-685

← 1 2 3 4 5 6 →